BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 30800129)

  • 1. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
    Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
    Front Immunol; 2019; 10():179. PubMed ID: 30800129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 9 and 21 have different ligand recognition profiles and cooperatively mediate activity of CpG-oligodeoxynucleotides in zebrafish.
    Yeh DW; Liu YL; Lo YC; Yuh CH; Yu GY; Lo JF; Luo Y; Xiang R; Chuang TH
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20711-6. PubMed ID: 24282308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chicken TLR21 acts as a functional homologue to mammalian TLR9 in the recognition of CpG oligodeoxynucleotides.
    Brownlie R; Zhu J; Allan B; Mutwiri GK; Babiuk LA; Potter A; Griebel P
    Mol Immunol; 2009 Sep; 46(15):3163-70. PubMed ID: 19573927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-Like Receptor 21 of Chicken and Duck Recognize a Broad Array of Immunostimulatory CpG-oligodeoxynucleotide Sequences.
    Chuang YC; Tseng JC; Yang JX; Liu YL; Yeh DW; Lai CY; Yu GY; Hsu LC; Huang CM; Chuang TH
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33147756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.
    Hanagata N
    Int J Nanomedicine; 2012; 7():2181-95. PubMed ID: 22619554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Stranded DNA Immune Modulators with Unmethylated CpG Motifs: Structure and Molecular Recognition by Toll-Like Receptor 9.
    Fehér K
    Curr Protein Pept Sci; 2019; 20(11):1060-1068. PubMed ID: 31470785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG-oligodeoxynucleotides developed for grouper toll-like receptor (TLR) 21s effectively activate mouse and human TLR9s mediated immune responses.
    Yeh DW; Lai CY; Liu YL; Lu CH; Tseng PH; Yuh CH; Yu GY; Liu SJ; Leng CH; Chuang TH
    Sci Rep; 2017 Dec; 7(1):17297. PubMed ID: 29229937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG ODN 2102 promotes antibacterial immune responses and enhances vaccine-induced protection in golden pompano (Trachinotusovatus).
    Chen X; Wu Y; Qiu Y; Li P; Cao Z; Zhou Y; Sun Y
    Fish Shellfish Immunol; 2023 Jun; 137():108783. PubMed ID: 37137380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of TLR9 agonist CpG oligodeoxynucleotides on the intestinal immune response of cobia (Rachycentron canadum).
    Byadgi O; Puteri D; Lee JW; Chang TC; Lee YH; Chu CY; Cheng TC
    J Immunol Res; 2014; 2014():273284. PubMed ID: 24991578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide.
    Chen L; Arora M; Yarlagadda M; Oriss TB; Krishnamoorthy N; Ray A; Ray P
    J Immunol; 2006 Aug; 177(4):2373-83. PubMed ID: 16887999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
    Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
    J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG ODN mimicking CpG rich region of myxosporean Myxobolus supamattayai stimulates innate immunity in Asian sea bass (Lates calcarifer) and defense against Streptococcus iniae.
    U-Taynapun K; Chirapongsatonkul N; Itami T; Tantikitti C
    Fish Shellfish Immunol; 2016 Nov; 58():116-124. PubMed ID: 27629917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
    Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
    Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.
    Mutwiri G
    Vet Immunol Immunopathol; 2012 Jul; 148(1-2):85-9. PubMed ID: 21700345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
    Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
    J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
    Vollmer J
    Expert Opin Biol Ther; 2005 May; 5(5):673-82. PubMed ID: 15934842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation.
    Jurk M; Vollmer J
    BioDrugs; 2007; 21(6):387-401. PubMed ID: 18020622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.